{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:12:50Z","timestamp":1789726370419,"version":"4.0.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Daptomycin pulmonary eosinophilia (DPE) has been well described in case reports and reporting from the Food and Drug Administration. We report 3 eosinophilic syndromes associated with daptomycin use.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This is a retrospective review of all patients who received daptomycin (inpatient or outpatient) from 2010 to 2020 at the Veterans Affairs Portland Healthcare System. Patients who developed DPE while receiving daptomycin were evaluated to determine risk factors. Data collected included daptomycin dose and duration, body mass index, creatinine clearance, and peripheral eosinophilia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 330 patients who received daptomycin, 81.5% developed a peripheral eosinophilia, with 109 (33%) developing peripheral eosinophilia \u22655%. Fifty-one (16%) met criteria for DPE. Primary DPE occurred in 38 of the 51 patients with a median 26 days of treatment, and 49% had peripheral eosinophilia \u22655%. Re-exposure DPE occurred in the other 13 patients and occurred a median of 3 days after initiation of daptomycin. The presence of an elevated peripheral eosinophilia of \u22655% during daptomycin usage was significantly associated with primary (odds ratio [OR], 2.23; 95% CI, 1.2\u20134.09; P\u2005=\u2005.008) and re-exposure DPE (OR, 12; 95% CI, 1.6\u2013103; P\u2005=\u2005.003). All patients recovered after withdrawal of daptomycin without complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There are 3 daptomycin eosinophilic syndromes: peripheral eosinophilia, primary DPE occurring about 4 weeks into therapy, and re-exposure DPE. Elevated peripheral eosinophilia \u22655% was a risk factor for both primary and re-exposure DPE, but still identified about half the cases. Peripheral eosinophilia should be carefully monitored during daptomycin treatment, and clinicians should be aware that prior eosinophilia may predict an acute pulmonary reaction upon daptomycin re-exposure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac065","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T15:30:49Z","timestamp":1647444649000},"source":"Crossref","is-referenced-by-count":19,"title":["Eosinophilic Syndromes Associated With Daptomycin Use: Re-exposure Hypersensitivity Pneumonitis and Prior Peripheral Eosinophilia"],"prefix":"10.1093","volume":"9","author":[{"given":"Katelyn A","family":"West","sequence":"first","affiliation":[{"name":"VA Portland Healthcare System, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sheeti","sequence":"additional","affiliation":[{"name":"VA Portland Healthcare System, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Tamura MacKay","sequence":"additional","affiliation":[{"name":"VA Portland Healthcare System, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6235-8978","authenticated-orcid":false,"given":"Graeme N","family":"Forrest","sequence":"additional","affiliation":[{"name":"VA Portland Healthcare System, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"2022031615304144700_CIT0001","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1128\/AAC.44.11.2948-2953.2000","article-title":"Once-daily dosing in dogs optimizes daptomycin safety.","volume":"44","author":"OlesonBerman","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2022031615304144700_CIT0002","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.","volume":"355","author":"FowlerBoucher","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031615304144700_CIT0003","first-page":"1240","article-title":"Development of daptomycin susceptibility breakpoints for Enterococcus faecium and revision of the breakpoints for other enterococcal species by the clinical and laboratory standards institute.","volume":"70","author":"Satlin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022031615304144700_CIT0004","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s10096-011-1500-y","article-title":"Safety analysis of high dose (&gt;6\u00a0mg\/kg\/day) daptomycin in patients with concomitant statin therapy.","volume":"31","author":"Parra-Ruiz","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2022031615304144700_CIT0005","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/11597460-000000000-00000","article-title":"Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports.","volume":"35","author":"Kim","year":"2012","journal-title":"Drug Saf"},{"key":"2022031615304144700_CIT0006","first-page":"e2899","article-title":"Daptomycin-induced acute eosinophilic pneumonia.","volume":"10","author":"Kumar","year":"2018","journal-title":"Cureus"},{"key":"2022031615304144700_CIT0007","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3109\/00365548.2013.805427","article-title":"Daptomycin-induced acute eosinophilic pneumonia: analysis of the current data and illustrative case reports.","volume":"45","author":"Phillips","year":"2013","journal-title":"Scand J Infect Dis"},{"key":"2022031615304144700_CIT0008","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/0091270004269562","article-title":"The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects.","volume":"45","author":"Dvorchik","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"2022031615304144700_CIT0009","first-page":"2049936118820230","article-title":"Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight.","volume":"6","author":"Fox","year":"2019","journal-title":"Ther Adv Infect Dis"},{"key":"2022031615304144700_CIT0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2169\/internalmedicine.9010-17","article-title":"Daptomycin-induced eosinophilic pneumonia and a review of the published literature.","volume":"57","author":"Higashi","year":"2018","journal-title":"Intern Med"},{"key":"2022031615304144700_CIT0011","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/20009666.2018.1475188","article-title":"Daptomycin associated eosinophilic pneumonia: case report and differential diagnoses.","volume":"8","author":"Basnet","year":"2018","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"2022031615304144700_CIT0012","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/cid\/ciy287","article-title":"Effect of statin coadministration on the risk of daptomycin-associated myopathy.","volume":"67","author":"Dare","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022031615304144700_CIT0013","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1515\/dmdi-2012-0033","article-title":"Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.","volume":"28","author":"Golightly","year":"2013","journal-title":"Drug Metabol Drug Interact"},{"key":"2022031615304144700_CIT0014","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofab568","article-title":"Identification of risk factors for daptomycin-associated creatine phosphokinase elevation and development of a risk prediction model for incidence probability.","volume":"8","author":"Samura","year":"2021","journal-title":"Open Forum Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/4\/ofac065\/42924589\/ofac065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/4\/ofac065\/42924589\/ofac065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T15:31:08Z","timestamp":1647444668000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac065\/6549660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac065","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2022,3,16]]},"article-number":"ofac065"}}